ERRα Estrogen-Related Receptor-α (ERRα), which belongs to the nuclear receptor subfamily, is a viable target for NAFLD and that the ERRα agonist may serve as an intriguing pharmacological option for management of metabolic diseases (Mao et al., 2022). This evidence concerns the gene ESRRA and metabolic disease.